Home > Journals > Minerva Cardioangiologica > Past Issues > Minerva Cardioangiologica 2011 April;59(2) > Minerva Cardioangiologica 2011 April;59(2):187-95

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

  CATHETER ABLATION TECHNIQUES 

Minerva Cardioangiologica 2011 April;59(2):187-95

Copyright © 2011 EDIZIONI MINERVA MEDICA

language: English

Antiarrhythmic drugs management in patients with atrial fibrillation: the new guidelines

Haitsma D. B., De Groot N. M. S., Jordaens L.

Department of Cardiology/electrophysiology, Erasmus Medical Center, Thoraxcentrum, Rotterdam, The Netherlands


PDF


Antiarrhythmic drug therapy will continue to play an important role in the treatment of atrial fibrillation (AF). Pharmacological therapy is focused on AF symptom relief and on prevention of tachycardiomyopathy. The choice between the various anti-arrhythmic drugs available, either for rate or rhythm control, mainly depends on the underlying cardiac disease, type of AF and possible side-effects. New anti-arrhythmic drugs in the guidelines — vernakalant and dronedarone — are promising, but further research is required to explore their role in treatment of patients with AF. In this review, we will discuss the role of antiarrhythmic drugs in management of patients with AF according to the new AF guidelines of the European Society of Cardiology.

top of page